Brainstorm Cell (BCLI)

$0.84 -0.33 (-28.21%)
Market Cap 11.51M
Revenue (ttm) 0.00
Net Income (ttm) -11.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.16
Volume 819,600
Avg Vol 1,676,626
Day's Range N/A - N/A
Shares Out 9.84M
Stochastic %K 34%
Beta 0.22
Analysts Strong Sell
Price Target $7.50

Company Profile

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 488 0460
Address:
1325 Avenue of Americas, 28th Floor, New York, United States
ALSCellTherapy
ALSCellTherapy Jun. 24 at 11:20 PM
$BCLI
1 · Reply
Pipemajors82
Pipemajors82 Jun. 23 at 4:01 PM
$BCLI volume starting to creep up. Coming up on 1 yr for CP.
0 · Reply
ALSCellTherapy
ALSCellTherapy Jun. 22 at 8:45 PM
$BCLI $1++ on its way! Let's get NurOwn in bodies!!!
1 · Reply
ALSCellTherapy
ALSCellTherapy Jun. 22 at 8:43 PM
$BCLI
0 · Reply
HUMBL4Now
HUMBL4Now Jun. 22 at 3:24 PM
$BCLI maybe the one year anniversary of the CP is the golden date? That puts us about a week and a half out. If they let the one year mark come and go that’s just sad.
1 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 22 at 12:01 PM
$BCLI Another decision just reversed. https://www.reuters.com/business/healthcare-pharmaceuticals/fda-reverse-rejection-regenxbios-rare-disease-drug-wsj-reports-2026-06-22/
0 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 18 at 3:45 AM
$BCLI Following the closed door meeting with FDA. Our friends in the Huntington disease community just saw a reversal. NurOwn next in line. https://www.davemanuel.com/2026/05/05/fda-reversal-uniqure-amt-130-huntingtons-disease-150-years/
2 · Reply
afc2881
afc2881 Jun. 17 at 9:12 PM
$BCLI Because stocktwits stopped updating our pps!
0 · Reply
80xEddiep
80xEddiep Jun. 17 at 9:09 PM
$BCLI why does the chart correctly show it around .85 but the price at the top has said .67 for months?
2 · Reply
cccfrhk
cccfrhk Jun. 17 at 4:36 PM
$BCLI Let's hope the FDA will soften its stance on BCLI stem cell therapy on ALS like what it just did for QURE gene therapy for Huntington disease. Desperate dying ALS patients and their families deserve the much needed but ever delayed compassion from the FDA. It's time for the authorities to right their wrongs, not just ALS but many other health/sick care decisions.
0 · Reply
Latest News on BCLI
No data available.
ALSCellTherapy
ALSCellTherapy Jun. 24 at 11:20 PM
$BCLI
1 · Reply
Pipemajors82
Pipemajors82 Jun. 23 at 4:01 PM
$BCLI volume starting to creep up. Coming up on 1 yr for CP.
0 · Reply
ALSCellTherapy
ALSCellTherapy Jun. 22 at 8:45 PM
$BCLI $1++ on its way! Let's get NurOwn in bodies!!!
1 · Reply
ALSCellTherapy
ALSCellTherapy Jun. 22 at 8:43 PM
$BCLI
0 · Reply
HUMBL4Now
HUMBL4Now Jun. 22 at 3:24 PM
$BCLI maybe the one year anniversary of the CP is the golden date? That puts us about a week and a half out. If they let the one year mark come and go that’s just sad.
1 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 22 at 12:01 PM
$BCLI Another decision just reversed. https://www.reuters.com/business/healthcare-pharmaceuticals/fda-reverse-rejection-regenxbios-rare-disease-drug-wsj-reports-2026-06-22/
0 · Reply
AshvsEvilDead
AshvsEvilDead Jun. 18 at 3:45 AM
$BCLI Following the closed door meeting with FDA. Our friends in the Huntington disease community just saw a reversal. NurOwn next in line. https://www.davemanuel.com/2026/05/05/fda-reversal-uniqure-amt-130-huntingtons-disease-150-years/
2 · Reply
afc2881
afc2881 Jun. 17 at 9:12 PM
$BCLI Because stocktwits stopped updating our pps!
0 · Reply
80xEddiep
80xEddiep Jun. 17 at 9:09 PM
$BCLI why does the chart correctly show it around .85 but the price at the top has said .67 for months?
2 · Reply
cccfrhk
cccfrhk Jun. 17 at 4:36 PM
$BCLI Let's hope the FDA will soften its stance on BCLI stem cell therapy on ALS like what it just did for QURE gene therapy for Huntington disease. Desperate dying ALS patients and their families deserve the much needed but ever delayed compassion from the FDA. It's time for the authorities to right their wrongs, not just ALS but many other health/sick care decisions.
0 · Reply
Cellsci
Cellsci Jun. 17 at 12:01 PM
$BCLI exosomes, Bcli many years behind https://www.cbc.ca/news/canada/london/world-first-burn-treatment-helps-western-student-recover-from-injuries-suffered-in-frat-house-fire-9.7237546
0 · Reply
DoctorJT
DoctorJT Jun. 16 at 2:56 AM
$BCLI pushing Clene again today. Not a peep about the CP pending for almost a year now. Great job getting ppl onboard the NurOwn train Chaim. How do most advocacy orgs hate NurOwn. Only one reason I can think of. https://x.com/iamalsorg/status/2066662165235323051?s=46
1 · Reply
HUMBL4Now
HUMBL4Now Jun. 15 at 8:32 PM
$BCLI cmon BCLI let’s gooo….have that former associate commissioner set up a meeting with the new FDA team THIS WEEK!…you guys need to be acting with EXTREME URGENCY!!!!
1 · Reply
mfglola
mfglola Jun. 13 at 5:11 PM
$BCLI Corestem announced late last year that they would seek a Type C meeting with FDA to review their phase 3 results which failed but showed significant improvement in ALSFRS, CAFS, and SVC in a slow progressor subgroup. At the time, the CEO bought $1MM in shares as they anticipated final Korean approval in Q1 2026 and submitting a BLA in Q3 2026. Crickets since then although they did set up US headquarters in Winston Salem. There is expectation of a Korean final decision shortly. Will be interesting if the BLA is submitted and any impact on CP...
1 · Reply
DoctorJT
DoctorJT Jun. 11 at 2:59 PM
$BCLI @ALSCellTherapy we’re currently down 7.08%, don’t forget to take a pic and post it here, just like you did on the up day yesterday. Thx in advance.
2 · Reply
kaisersosay
kaisersosay Jun. 11 at 12:16 AM
$BCLI Brainstorm's Ph3 trial eas rejected by the FDA 2 1/2 years ago. Has there been any progress made since then? Why hasn't a new trial already been initiated?
1 · Reply
ALSCellTherapy
ALSCellTherapy Jun. 10 at 7:29 PM
$BCLI
1 · Reply
mfglola
mfglola Jun. 10 at 1:02 AM
$BCLI Meanwhile Coya has begun dosing patients in the 24 wk extension study and remain on target for top line readout Q1 2027. Coya also has an exosome platform.
2 · Reply
Pipemajors82
Pipemajors82 Jun. 8 at 9:04 PM
$BCLI https://www.facebook.com/share/17vhUSgEzJ/
0 · Reply
Condo3e
Condo3e Jun. 8 at 7:30 PM
$BCLI The exosome platform is. Strategics love: Novel modalities Manufacturing IP Multi‑indication potential IND‑ready platforms Scalable biologics This is BrainStorm’s exosome program to a T.
1 · Reply
Condo3e
Condo3e Jun. 8 at 6:58 PM
$BCLI The BioSpace article shows: Pitts was a former critic Pitts now believes BrainStorm is doing “very exciting science” Pitts joined the board before funding arrived Pitts says the company’s attitude has changed Pitts is a regulatory strategist, not a bench scientist Pitts would not join a company with no plan
0 · Reply
Condo3e
Condo3e Jun. 8 at 6:21 PM
$BCLI Pitts is positioning BrainStorm for a strategic acquisition. Not for NurOwn. For the exosome platform. NurOwn is the emotional story. The exosome platform is the strategic story. Pitts joined for the strategic story.
0 · Reply